Table 11.

Recommendations for co-administering antiretroviral therapy with rifabutin^a

Drug	Antiretroviral dosage adjustment	Rifabutin dosage adjustment
Boosted protease inhibitors (LPV/r, FPV/r, DRV/r, SQV/r, ATV/r)	None	150 mg every 2 days (or 3×/week)
Efavirenz	None	450 mg/day
Nevirapine	None, but cave hepatotoxicity
Delavirdine, etravirine	Should not be co-administered
Maraviroc	Depending on other antiretroviral drugs	Standard dosage
Raltegravir	No data	No data
Nucleoside reverse-transcriptase inhibitors (NRTIs)	None	Standard dosage

^aModified from CDC 2007 [228]

Unboosted protease inhibitors are no longer recommended due to insufficient plasma levels. Consider TDM